Based on product, the HIV diagnosis market is categorized into consumables, software & services, and instruments. Out of these, during the historical period (2013–2016), consumables dominated the market, and these are predicted to continue dominating it during the forecast period. This is attributed to the surging cost of the reagents used during HIV tests and the advent of various innovative products in the market. The consumables are further bifurcated into assays, kits & reagents, and others.
This is attributed to the fact that the majority of HIV tests are performed at laboratories. In addition, these laboratories provide the benefit of the latest instruments along with skilled professionals who can conduct various tests to confirm the diagnosis of HIV infection. As per the Joint United Nations Programme on HIV/AIDS (UNAIDS), the incidence of HIV/AIDS surged by 2.8 million from 2011 to 2015, and around 36.7 million people tested positive for HIV across the globe. In 2015, approximately 40.0% of the people suffering from HIV were not aware of their status.
The growing prevalence of the disease is predicted to boost the demand for diagnosis products, which, in turn, would result in the growth of the HIV diagnosis market. HIV easily spreads through a used needle or transfusion of infected blood to a healthy person. In the past few years, many low and middle-income as well as developing nations have witnessed an increase in the healthcare expenditure for the purpose of reducing the incidence of HIV.
Taking into account the rising incidence of HIV cases, UNAIDS estimated that around $26.2 billion will be needed to respond to the epidemic of HIV infection in 2020 and nearly $23.9 billion for the same purpose in 2030. The overall healthcare expenditure on HIV and related activities is expected to augment the HIV diagnosis market growth.
Hence, the growing incidence of HIV/AIDS and significant healthcare expenditure on diagnosis and related activities are being witnessed as the major growth drivers of the market.